The Japanese media reported that Daiichi Sankyo was in talks with several companies to sell its over-the-counter drug unit, Daiichi Sankyo Healthcare, but the company has denied the rumors.
"Although Daiichi Sankyo is constantly examining the potential for a variety of strategic developments with the aim of sustainable business growth, this reporting is not correct," the company said in a statement on its website.
Reuters reported earlier this year that Japan’s fourth-biggest drugmaker by sales had hired JPMorgan to advise on the potential sale of the unit. According to the recent rumors, with the final sale price was likely to reach around 100 billion yen ($900 million).
Read the Reuters coverage.